Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’

Patrick Schöffski, Olivier Mir, Bernd Kasper, Zsuzsanna Pápai, Jean‐Yves Blay, Antoîne Italiano, Charlotte Benson, Kateřina Kopečková, Nasim Ali, Palma Dileo, A. Lecesne, Franka Menge, Sophie Cousin, Eva Wardelmann, Agnieszka Woźniak, Sandrine Marréaud, Saskia Litière, Facundo Zaffaroni, Axelle Nzokirantevye, Isabelle Vanden Bempt, Hans Gelderblom